In the history of SPPARM development, some have shown dual activity, such as aleglitazar, a PPARα/γ agonist (terminated) and elafibranor (previously known as GFT505), a PPARα/δ agonist, which had been targeted to the management of NASH. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.